Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Advisory Alpha LLC

Advisory Alpha LLC lowered its position in Bristol-Myers Squibb (NYSE:BMY) by 11.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 8,638 shares of the biopharmaceutical company’s stock after selling 1,128 shares during the period. Advisory Alpha LLC’s holdings in Bristol-Myers Squibb were worth $489,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Missouri Trust & Investment Co lifted its position in Bristol-Myers Squibb by 347.8% during the fourth quarter. Missouri Trust & Investment Co now owns 1,030 shares of the biopharmaceutical company’s stock valued at $58,000 after purchasing an additional 800 shares during the period. Dakota Wealth Management boosted its stake in shares of Bristol-Myers Squibb by 377.4% in the fourth quarter. Dakota Wealth Management now owns 260,293 shares of the biopharmaceutical company’s stock worth $14,722,000 after buying an additional 205,772 shares during the last quarter. Eads & Heald Wealth Management raised its position in Bristol-Myers Squibb by 2.7% during the fourth quarter. Eads & Heald Wealth Management now owns 19,323 shares of the biopharmaceutical company’s stock valued at $1,093,000 after acquiring an additional 505 shares in the last quarter. XML Financial LLC lifted its holdings in Bristol-Myers Squibb by 0.8% in the fourth quarter. XML Financial LLC now owns 75,068 shares of the biopharmaceutical company’s stock valued at $4,246,000 after acquiring an additional 583 shares during the period. Finally, Genesis Private Wealth LLC purchased a new stake in Bristol-Myers Squibb in the 4th quarter worth approximately $298,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

BMY has been the subject of several analyst reports. BMO Capital Markets boosted their target price on shares of Bristol-Myers Squibb from $57.00 to $61.00 and gave the company a “market perform” rating in a research note on Tuesday, November 12th. TD Cowen increased their target price on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. Barclays lifted their price target on Bristol-Myers Squibb from $42.00 to $43.00 and gave the company an “underweight” rating in a research note on Monday, October 7th. Truist Financial raised their price objective on Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. Finally, Jefferies Financial Group raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and lifted their price target for the stock from $63.00 to $70.00 in a research note on Monday, December 16th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, four have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $56.27.

Insider Buying and Selling at Bristol-Myers Squibb

In related news, SVP Phil M. Holzer sold 700 shares of the business’s stock in a transaction on Monday, November 4th. The stock was sold at an average price of $55.62, for a total value of $38,934.00. Following the sale, the senior vice president now owns 11,760 shares in the company, valued at approximately $654,091.20. The trade was a 5.62 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Samit Hirawat bought 1,830 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The shares were purchased at an average cost of $54.67 per share, for a total transaction of $100,046.10. Following the purchase, the executive vice president now owns 62,109 shares in the company, valued at $3,395,499.03. This represents a 3.04 % increase in their position. The disclosure for this purchase can be found here. 0.09% of the stock is owned by corporate insiders.

Bristol-Myers Squibb Trading Up 0.1 %

BMY opened at $57.11 on Thursday. The stock has a market capitalization of $115.83 billion, a PE ratio of -15.91, a P/E/G ratio of 1.98 and a beta of 0.45. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $61.08. The company has a debt-to-equity ratio of 2.83, a quick ratio of 1.09 and a current ratio of 1.24. The business’s 50 day moving average price is $57.42 and its 200 day moving average price is $52.33.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping analysts’ consensus estimates of $1.49 by $0.31. The business had revenue of $11.89 billion during the quarter, compared to analysts’ expectations of $11.26 billion. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The company’s revenue was up 8.4% compared to the same quarter last year. During the same period in the prior year, the business posted $2.00 EPS. As a group, equities research analysts expect that Bristol-Myers Squibb will post 0.92 EPS for the current year.

Bristol-Myers Squibb Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, February 3rd. Investors of record on Friday, January 3rd will be given a dividend of $0.62 per share. The ex-dividend date of this dividend is Friday, January 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.34%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -69.08%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.